Fusion Medical Technologies Inc., of Mountain View, Calif., promoted Christopher Dauer to vice president marketing, North America.
Genometrix Inc., of The Woodlands, Texas, appointed David Jorden vice president and chief financial officer.
Genomica Corp., of Boulder, Colo., named Kenneth Rubin executive vice president of commercial development.
Helicon Therapeutics Inc., of Cold Spring Harbor, N.Y., elected George Carmany III chairman and CEO.
ICAgen Inc., of Research Triangle Park, N.C., appointed James Heyward Hull senior vice president of development and regulatory affairs.
ICN Pharmaceuticals Inc., of Costa Mesa, Calif., appointed Johnson Yiu-Nam Lau senior vice president research and development.
InterMune Pharmaceuticals Inc., of Palo Alto, Calif., elected to its board of directors Wayne Hockmeyer, a founder and CEO of MedImmune Inc.
King Pharmaceuticals Inc., of Bristol, Tenn., named Michael Jolly executive vice president of clinical research and development.
Mosaic Technologies Inc., of Boston, named to its board of directors Patrick Sullivan, president and CEO of Cytyc Corp.
Pharma Mar SA, of Madrid, Spain, named Immaculada Abella and Jose Sanchez-Puelles heads of marketing and discovery.
Pilot Therapeutics Inc., of Winston-Salem, N.C., elected to its board of directors Santo Costa, vice chairman of Quintiles Transnational Corp.
ProdiGene, of College Station, Texas, named Donald Emlay director of regulatory affairs.
Tibotec, of Rockville, Md., named to its board of directors Andre Bergen, chief financial officer of Agfa-Gevaert, and Felix Theeuwes, former president of research and development with Alza Corp.
Variagenics Inc., of Cambridge, Mass., appointed Richard Shea chief financial officer.
ChiRex Inc., of Stamford, Conn., elected to its board of directors David Stevenson, a former partner with Arthur Andersen LLP.
UroGenesys Inc., of Santa Monica, Calif., hired Mary Anderson as director of business development.
AlphaVax Inc., of Durham, N.C., elected to its board of directors Ron Saldarini, former president of Wyeth-Lederle Vaccines and Pediatrics, and Matthew Megaro, president and CEO of Quill Medical Inc.
Immunex Corp., of Seattle, appointed Dawn Viveash vice president, regulatory affairs, and Andrew Hull vice president, specialty therapeutics marketing.
GlycoDesign Inc., of Toronto, appointed Leonard Walt vice president, clinical development and regulatory affairs.
Collateral Therapeutics Inc., of San Diego, named to its board of directors B. Mason Flemming Jr., managing director of Flemming, Lessard & Shields, an investment banking firm.
Zila Inc., of Phoenix, Ariz., named Thomas Laughlin chief operating officer.